Alphen A.D. Rijn, Netherlands

Menzo Jans Emco Havenga

USPTO Granted Patents = 16 


Average Co-Inventor Count = 3.3

ph-index = 7

Forward Citations = 129(Granted Patents)


Location History:

  • Alphen aan de Rijn, NL (2005)
  • Rijn, NL (2007)
  • Alphen aan den Rijn, NL (2010 - 2013)
  • Alphen a/d Rijn, NL (2005 - 2016)

Company Filing History:


Years Active: 2005-2016

Loading Chart...
Loading Chart...
16 patents (USPTO):Explore Patents

Title: Menzo Jans Emco Havenga: Innovator in Biotechnology

Introduction

Menzo Jans Emco Havenga is a prominent inventor based in Alphen A.D. Rijn, Netherlands. He has made significant contributions to the field of biotechnology, particularly in the development of cell lines and vaccines. With a total of 16 patents to his name, Havenga's work has had a profound impact on gene therapy and vaccine development.

Latest Patents

Havenga's latest patents include innovations such as a packaging cell line that complements recombinant adenoviruses based on serotypes from subgroup B, specifically adenovirus type 35. This cell line is derived from primary, diploid human cells transformed by adenovirus E1 sequences. The sequences are operatively linked to regulatory sequences that enable transcription and translation of encoded proteins. Additionally, he has developed multivalent vaccines comprising recombinant viral vectors that encode antigens from tuberculosis-causing bacilli. These vaccines utilize specific protease recognition sites to link antigens, enhancing the immune response.

Career Highlights

Throughout his career, Havenga has worked with notable organizations such as Crucell Holland B.V. and Aeras Global TB Vaccine Foundation. His expertise in biotechnology has led to advancements in the production of recombinant adenoviruses and therapeutic proteins. His innovative approaches have positioned him as a leader in the field.

Collaborations

Havenga has collaborated with esteemed colleagues,

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…